(Approval lapsed 31/08/2022) Thiotepa for Injection, USP 15mg/vial (Novadoz)
Section 19A approved medicine
(Approval lapsed 31/08/2022) Thiotepa for Injection, USP 15mg/vial (Novadoz)
Section 19A approval holder
Reach Pharmaceuticals Pty Ltd ABN 25 623 897 183
Phone
0478 061 879
Approved until
Status
Lapsed
Indication(s)
As conditioning treatment prior to haematopoietic progenitor cell transplantation